Breaking News Instant updates and real-time market news.

AMGN

Amgen

$172.23

1.97 (1.16%)

17:01
11/29/17
11/29
17:01
11/29/17
17:01

Amgen: STRIVE results show significant reduction in mean monthly migraine days

Amgen announced that the New England Journal of Medicine published positive results from the six-month Phase 3 STRIVE study evaluating Aimovig versus placebo for the prevention of episodic migraine. Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study. Patients taking Aimovig experienced a significant reduction in mean monthly migraine days and were significantly more likely to achieve a 50 percent or greater reduction in monthly migraine days than those taking placebo. Patients reported significant improvements on key measures assessing the impact of migraine on their lives when taking Aimovig, based on the Migraine Physical Function Impact Diary - a novel patient-reported outcomes instrument validated to specifically measure the impact of migraine on physical functioning. Aimovig is the first and only fully human monoclonal antibody designed to specifically block the calcitonin gene-related peptide receptor; CGRP plays a critical role in migraine activation. "STRIVE is the first fully reported Phase 3 study of the CGRP pathway monoclonal antibodies, and it clearly shows that blocking this pathway can reduce the impact of migraine," said Peter Goadsby, M.D., Ph.D., FAHS, director, NIHR-Wellcome Trust King's Clinical Research Facility and professor of Neurology, King's College Hospital, London. "The results of STRIVE represent a real transition for migraine patients from poorly understood, repurposed treatments, to a specific migraine-designed therapy. STRIVE, as with the monoclonal antibody developments generally, represents an incredibly important step forward for migraine understanding and migraine treatment."

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 18

    Jan

  • 03

    Feb

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN Amgen
$172.23

1.97 (1.16%)

10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold from Buy at Argus
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold at Argus on secular slowdown in sales of top drugs
As reported earlier, Argus analyst David Toung downgraded Amgen to Hold from Buy, noting a "secular" slowdown in sales of the company's top three products - Enbrel, Neulasta and Aranesp. Toung says the sales of growth prospects Prolia, Kyprolis and Repatha are not yet large enough to offset the declines in the three established drugs which face generic competition after losing patent protection. The analyst notes that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal challenges.
11/29/17
PIPR
11/29/17
NO CHANGE
Target $190
PIPR
Overweight
Piper still bullish on Amgen after management meeting
Piper Jaffray analyst Christopher Raymond says he remains bullish on Amgen shares after hosting the company's management at his firm's healthcare conference. The analyst sees near-term pipeline catalysts from Amgen's immuno-oncology approach, which he sees coming more into focus, Repatha label expansion, Parsabiv launch and Aimovig approval/launch next year. Raymond maintains an Overweight rating on the shares with a $190 price target.

TODAY'S FREE FLY STORIES

CSX

CSX

$52.93

-4.38 (-7.64%)

15:18
12/16/17
12/16
15:18
12/16/17
15:18
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

CBOE Holdings

$126.37

0.31 (0.25%)

11:22
12/16/17
12/16
11:22
12/16/17
11:22
Periodicals
CBOE should not be treated as 'set and forget,' Barron's says »

Bitcoin futures have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

11:17
12/16/17
12/16
11:17
12/16/17
11:17
Periodicals
Disney/Fox 'a murky web of deals within deals,' Barron's says »

Walt Disney's (DIS)…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.83

1.44 (2.08%)

10:53
12/16/17
12/16
10:53
12/16/17
10:53
Periodicals
Alaska air should bounce back in 2018, Barron's says »

While shares of Alaska…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

10:42
12/16/17
12/16
10:42
12/16/17
10:42
Periodicals
Spark Therapeutics selloff may be overdone, Barron's says »

Spark Therapeutics shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

AAPL

Apple

$173.97

1.75 (1.02%)

10:29
12/16/17
12/16
10:29
12/16/17
10:29
Periodicals
New Apple iPhone features also bring software bugs, Barron's says »

While each new Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

10:19
12/16/17
12/16
10:19
12/16/17
10:19
Periodicals
More consolidation to come after Disney/Fox deal, Barron's says »

Netflix (NFLX) success…

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

09:22
12/16/17
12/16
09:22
12/16/17
09:22
Periodicals
Exxon disclosure of climate-change regulation impact has risks, Barron's says »

In a filing with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

07:58
12/16/17
12/16
07:58
12/16/17
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

T

AT&T

$38.24

0.5 (1.32%)

CHTR

Charter

$322.31

-6.37 (-1.94%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

VZ

Verizon

$52.67

0.33 (0.63%)

NFLX

Netflix

$190.12

0.56 (0.30%)

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

FB

Facebook

$180.18

1.79 (1.00%)

TWTR

Twitter

$22.23

-0.35 (-1.55%)

GOOG

Alphabet

$1,064.19

15.04 (1.43%)

GOOGL

Alphabet Class A

$1,072.00

14.53 (1.37%)

DFS

Discover

$74.59

0.92 (1.25%)

SYF

Synchrony

$37.19

0.2 (0.54%)

COF

Capital One

$96.31

2.25 (2.39%)

OMF

OneMain Holdings

$25.50

0.25 (0.99%)

CIT

CIT Group

$49.78

0.64 (1.30%)

SC

Santander Consumer

$17.99

-0.29 (-1.59%)

SLM

Sallie Mae

$11.17

0.18 (1.64%)

AL

Air Lease

$45.80

1.07 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 14

    Dec

SHOO

Steven Madden

$44.15

1.15 (2.67%)

04:55
12/16/17
12/16
04:55
12/16/17
04:55
Conference/Events
Steven Madden management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 07

    Jan

  • 08

    Jan

STLD

Steel Dynamics

$39.85

0.01 (0.03%)

18:07
12/15/17
12/15
18:07
12/15/17
18:07
Earnings
Steel Dynamics sees Q4 EPS 48c-52c, consensus 55c »

"Despite a lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

House plans to vote…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Republicans release final tax bill proposal, CNBC reports »

Republicans have released…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$162.60

5.4 (3.44%)

17:37
12/15/17
12/15
17:37
12/15/17
17:37
Hot Stocks
McKesson awarded $400M government contract »

McKesson has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$60.94

0.11 (0.18%)

17:34
12/15/17
12/15
17:34
12/15/17
17:34
Syndicate
Breaking Syndicate news story on Ameren »

Ameren files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Akamai (AKAM), up…

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 13

    Dec

GRMN

Garmin

$58.36

-1.1 (-1.85%)

17:32
12/15/17
12/15
17:32
12/15/17
17:32
Recommendations
Garmin analyst commentary at Tigress Financial »

Garmin growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$322.82

5.81 (1.83%)

17:26
12/15/17
12/15
17:26
12/15/17
17:26
Hot Stocks
Lockheed Martin awarded $135.83M government contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

PG

Procter & Gamble

$91.89

0.89 (0.98%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
Peltz to join Procter & Gamble board effective March 1, 2018 »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.89 (0.98%)

, NVS

Novartis

$84.86

0.39 (0.46%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
P&G names Trian's Nelson Peltz, Novartis CEO Jimenez to board »

Procter & Gamble (PG)…

PG

Procter & Gamble

$91.89

0.89 (0.98%)

NVS

Novartis

$84.86

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

SNSS

Sunesis

$3.36

0.16 (5.00%)

17:16
12/15/17
12/15
17:16
12/15/17
17:16
Hot Stocks
Sunesis CEO Swisher to resign, Dayton Misfeldt named interim CEO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, BA

Boeing

$293.94

0.06 (0.02%)

17:09
12/15/17
12/15
17:09
12/15/17
17:09
Hot Stocks
AT&T CEO Stephenson resigns from Boeing board »

According to a regulatory…

T

AT&T

$38.24

0.5 (1.32%)

BA

Boeing

$293.94

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

HPE

HP Enterprise

$14.41

0.17 (1.19%)

17:03
12/15/17
12/15
17:03
12/15/17
17:03
Syndicate
Breaking Syndicate news story on HP Enterprise »

HP Enterprise files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

FSV

FirstService

$67.87

-0.54 (-0.79%)

17:02
12/15/17
12/15
17:02
12/15/17
17:02
Hot Stocks
Breaking Hot Stocks news story on FirstService »

Jay S. Hennick reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETP

Energy Transfer Partners

$17.50

0.08 (0.46%)

17:01
12/15/17
12/15
17:01
12/15/17
17:01
Hot Stocks
Energy Transfer gets FERC approval to place Rover Pipeline's 1B into service »

Energy Transfer Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.